ClinicalTrials.gg
Not yet recruitingNCT07901738Updated Oct 28, 2026

Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children

A Phase 3 interventional study of Zopapogene imadenovec-drba in Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis and Papillomavirus Infections, sponsored by Precigen, Inc. Not yet recruiting at 1 site in United States. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Precigen, Inc · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Recurrent respiratory papillomatosis with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Recurrent respiratory papillomatosis · United States.

Planned enrollment
11th of 16
15 · median 21
Started
2026
with 3 others
Phase 3
Only one
of the 20
Registered
20th of 20
by date
Lead sponsor
3 of 20
Precigen, Inc

Among the 20 studies in Recurrent respiratory papillomatosis with a site in United States, this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 3, and was the 20th registered.

Recurrent respiratory papillomatosis

32 studies on the registry are indexed under Recurrent respiratory papillomatosis; 9 are open to participants now.

Browse Recurrent respiratory papillomatosis studies →

Open to participants now

8 of the 20 studies in Recurrent respiratory papillomatosis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Recurrent respiratory papillomatosis studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Recurrent respiratory papillomatosis with a site in United States, or all of them as a file.
02

Study summary

Recurrent respiratory papillomatosis (RRP) is a rare disease in which wart-like growths caused by human papillomavirus (HPV) types 6 or 11 form in the airway. These growths can affect the voice and breathing and often come back after they are removed, meaning many children will need repeated surgeries to keep their airway open. There is no medicine approved to treat RRP in children.

This study is testing zopapogene imadenovec, an investigational immunotherapy designed to help the immune system recognize and control cells infected with HPV 6 and 11. Zopapogene imadenovec is approved in the United States for the treatment of adults with recurrent respiratory papillomatosis.

All participants in this study will receive zopapogene imadenovec; there is no placebo group. The study drug is given as four injections under the skin over about three months. Before the first injection, participants have a standard surgical procedure to remove visible growths. Participants are then followed for at least 12 months to see how many need further surgery, and are contacted periodically for up to five years after their last injection.

The study will enroll children in two age groups, starting with older children and opening to younger children only after safety has been reviewed.

03

Conditions studied

  • Recurrent Respiratory Papillomatosis (RRP)
  • Juvenile-onset Recurrent Respiratory Papillomatosis
  • Papillomavirus Infections
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age 1 to 17 years
  • Clinical diagnosis of RRP with confirmed papilloma
  • Laryngotracheal papillomas accessible for endoscopic debulking
  • At least 3 lifetime debulking procedures (the Day -1 procedure counts)
  • Active RRP, shown by at least 1 clinically indicated debulking procedure within the 12 months before treatment, including the Day -1 procedure. For participants who received systemic bevacizumab, the qualifying procedure must show recurrence of active disease after bevacizumab was stopped; if the Day -1 procedure is used, it must be clinically indicated for recurrent disease.
  • Willing to undergo endoscopic evaluation, operative interventions, and per protocol

Key Exclusion Criteria:

  • Any condition, therapy, or lab abnormality that would increase participation risk, impair receipt of protocol therapy, or confound interpretation of results, per the Investigator
  • Systemic (>2 mg/kg/day or >10 mg/day prednisone equivalent) or other within 14 days of dosing (inhaled, topical, intranasal, intra-ocular, and adrenal replacement doses permitted)
  • Any systemic or intralesional RRP treatment, including bevacizumab and agents, within 30 days or 3 half-lives of the prior treatment, whichever is longer
  • Any vaccine within 30 days before the first dose
  • Persisting Grade >1 toxicity from prior therapy (alopecia and Grade ≤2 events not posing a safety risk are acceptable)
  • History of heparin-induced thrombocytopenia (HIT) or vaccine-induced immune thrombotic thrombocytopenia (VITT)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Zopapogene imadenovec

    Participants receive four subcutaneous administrations of zopapogene imadenovec on Day 1, Week 2, Week 6, and Week 12, each in a different limb. Participants aged ≥6 to \<18 years receive 5 x 10\^11 particle units per injection; participants aged ≥1 to ≤5 years begin at 2.5 x 10\^11 particle units per injection with sentinel dosing. All participants undergo a standard-of-care debulking procedure on Day -1.

    Biological: Zopapogene imadenovec-drba

Interventions

06

What researchers measure

Primary outcomes

  1. Complete response rate

    Percentage of participants with a complete response, defined as no requirement for any clinically indicated debulking intervention during the 12 months following the last administration of zopapogene imadenovec.

    Time frame: 12 months following last administration of study drug

Secondary outcomes

  1. Number of participants with adverse events (AEs) and treatment-related AEs

    Incidence and severity of all AEs and of AEs assessed as related to zopapogene imadenovec, graded by NCI CTCAE version 6.0.

    Time frame: From first administration through 12 months after the last administration (treatment-related AEs through 28 days after the last administration)

  2. Time to first clinically indicated debulking intervention (duration of response)

    Interval from completion of zopapogene imadenovec treatment until the first clinically indicated debulking intervention, estimated by the Kaplan-Meier method.

    Time frame: From the last administration (Week 12) up to 5 years

  3. Objective response rate (ORR)

    Percentage of participants with a complete response or a partial response. Partial response is defined as at least a 50% decrease in the number of clinically indicated debulking interventions during the 12 months after treatment compared with the 12 months before treatment.

    Time frame: 12 months before the first administration and 12 months after the last administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jan 2029, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Oct 28, 2026
StartEst.
Dec 31, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2033
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07901738
Lead sponsor
Precigen, Inc
Responsible party
Sponsor
First posted
Oct 28, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2033 (estimated)
Last update
Oct 28, 2026

Study contacts

Eliza Argonza-Aviles
Contact
clinicaltrials@precigen.com
240-961-9869

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zopapogene imadenovec

Start the discussion